Charles E Rice

US Patent:

7338759, Mar 4, 2008

Filed:

May 23, 2001

Appl. No.:

10/276051

Inventors:

Charles M. Rice - New York NY, US
Keril J. Blight - St. Louis MO, US

Assignee:

Washington University - St. Louis MO

International Classification:

C12Q 1/70
C12Q 1/68
C12N 15/09
C12P 21/00
C12N 7/02
C12N 5/10
C07H 21/00

US Classification:

435 6, 435 691, 435 701, 4353201, 4352351, 435239, 435 5, 536 2372, 536 241

Abstract:

HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.

US Patent:

7674612, Mar 9, 2010

Filed:

Mar 3, 2006

Appl. No.:

11/366839

Inventors:

Charles Rice - New York NY, US
Brett D Lindenbach - New York NY, US
Matthew J Evans - New York NY, US
Christopher Jones - New York NY, US

Assignee:

The Rockefeller University - New York NY

International Classification:

C12N 15/09
C12N 15/51
C12N 7/00
C12N 7/01
C12N 7/04
C07H 21/00
C12N 15/00

US Classification:

4352351, 435 41, 435 691, 435239, 4353201, 536 237, 536 2372

Abstract:

The present invention provides infectious recombinant Hepatitis C Viruses (HCV), and vectors, cells and animals comprising the same. The present invention provides methods of producing infectious recombinant HCV, and their use in identifying anti-HCV therapeutic agents, as well as sequences of HCV associated with HCV pathogenesis.

US Patent:

7794942, Sep 14, 2010

Filed:

Dec 19, 2007

Appl. No.:

11/960391

Inventors:

Charles M. Rice - New York NY, US
Keril J. Blight - St. Louis MO, US

Assignee:

Washington University - St. Louis MO

International Classification:

C12Q 1/68
C12N 15/00
C12N 5/10
C12N 15/51

US Classification:

435 6, 435455, 435325, 4353201

Abstract:

HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.

US Patent:

7894996, Feb 22, 2011

Filed:

Feb 28, 2006

Appl. No.:

11/817309

Inventors:

Charles Rice - New York NY, US
Timothy Tellinghuisen - Royal Palm Beach FL, US
Joseph Marcotrigiano - New Brunswick NJ, US

Assignee:

The Rockefeller University - New York NY

International Classification:

G01N 23/00
G06G 7/58

US Classification:

702 19, 703 11

Abstract:

The present invention provides a crystallized N-terminal domain of an NS5A protein of hepatitis C virus, methods of producing the same and methods of use thereof. The present invention also relates to structural elements of the N-terminal domain of hepatitis C virus NS5A protein, and methods of inhibiting hepatitis C virus infection, replication and/or pathogenesis, by interacting with the same.

US Patent:

8021835, Sep 20, 2011

Filed:

May 4, 2007

Appl. No.:

12/299439

Inventors:

Charles Rice - New York NY, US
Matthew J. Evans - New York NY, US
Thomas Von Hahn - Hamburg, DE

Assignee:

The Rockefeller University - New York NY

International Classification:

C12Q 1/70
A61K 39/29

US Classification:

435 5, 4242281, 530350

Abstract:

The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed.

US Patent:

20060019245, Jan 26, 2006

Filed:

Jul 1, 2005

Appl. No.:

11/173792

Inventors:

Charles Rice - New York NY, US
Keril Blight - St. Louis MO, US

International Classification:

C12Q 1/70
C07H 21/04
C12N 7/00
C12N 15/86

US Classification:

435005000, 435456000, 435235100, 536023720

Abstract:

HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are methods for identifying HCV variant polynucleotides with increased transfection efficiencies. Additionally, methods for identifying one or more HCV sequence mutations that provide drug-resistant HCV variants are disclosed.

US Patent:

20090233266, Sep 17, 2009

Filed:

Mar 9, 2006

Appl. No.:

11/817782

Inventors:

Charles Rice - New York NY, US
Joseph Marcotrigiano - New Brunswick NJ, US
Ivo C. Lorenz - Brooklyn NY, US

Assignee:

The Rockefeller University - New York NY

International Classification:

C12Q 1/70
C07K 1/00

US Classification:

435 5, 530402

Abstract:

The present invention provides a crystallized C-terminal domain of an NS2 protein of hepatitis C virus, methods of producing the same and methods of use thereof. The present invention also relates to structural elements of the C-terminal domain of hepatitis C virus NS2 protein, and methods of inhibiting hepatitis C virus infection, replication and/or pathogenesis, by interacting with the same.

US Patent:

20100062419, Mar 11, 2010

Filed:

Oct 19, 2009

Appl. No.:

12/581597

Inventors:

Charles Rice - New York NY, US
Matthew J. Evans - New York NY, US
Brett D. Lindenbach - Hamden CT, US
Christopher Jones - New York NY, US

Assignee:

THE ROCKEFELLER UNIVERSITY - New York NY

International Classification:

C12Q 1/70
C12N 7/00
C07H 21/04

US Classification:

435 5, 4352351, 536 231

Abstract:

The present invention provides infectious recombinant Hepatitis C Viruses (HCV), and vectors, cells and animals comprising the same. The present invention provides methods of producing infectious recombinant HCV, and their use in identifying anti-HCV therapeutic agents, as well as sequences of HCV associated with HCV pathogenesis.